Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 24 Sept 2003 |
| Genmab, quarterly statement of shareholdings | 18 Sept 2003 |
| InvestorService: Genmab, Genmab to Present at UBS Global Life Sciences Conference 2003 | 18 Sept 2003 |
| Genmab, Genmab Achieves Milestone in Amgen License Agreement | 16 Sept 2003 |
| Genmab, Publishes Investment Memorandum | 29 Aug 2003 |